A Double-Blind, Randomised, Parallel-Group Study of Pitavastatin in Familial Hypercholesterolemia in Childhood

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221734

Enrollment

Registered

2012-03-05

Start date

2012-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial hypercholesterolemia

Interventions

investigational material(s) Generic name etc : NK-104 INN of investigational material : Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients diagnosed with familial hypercholesterolemia

Exclusion criteria

Exclusion criteria: 1. Previously taken pitavastatin 2. Need for other lipid lowering drugs 3. Diagnosed as homozygous familial hypercholesterolaemia 4. Requiring apheresis therapy

Design outcomes

Primary

Measure	Time frame
LDL-C Percent change from baseline LDL-C at Week 8 and Week 12	—

Secondary

Measure	Time frame
LDL-C,TC,TG,HDL-C,Apo-A1,Apo-B Percent change from baseline at each visit	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026